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PARAMETER-PARAMETER SEL DARAH MERAH, VITAMIN B12, FOLAT, 
ARAS HOMOSISTEINE DAN MUTAS GENE MTHFR DALAM KALANGAN 
WANITA MELAYU YANG TELAH MENOPAUS DAN HUBUNG KAIT 
DENGAN PENGGUNAAN TERAPI PENGGANTIAN HORMON 
 
ABSTRAK 
 
Latarbelakang: Hiperhomosisteinemia terjadi disebabkan oleh penurunan aras 
kofaktor-kofaktor (vitamin B12, B6 dan folat) dan / atau akibat kekurangan 
keberkesanan enzim methylene tetrahydrofolate  reductase (MTHFR). Keadaan ini telah 
dikaitkan dengan risiko kejadian ‘atherosclerosis’ yang merupakan salah satu faktor 
penyumbang kepada penyakit jantung koronari di kalangan wanita menopaus. Adalah 
tidak di ketahui samada perubahan pada parameter-parameter sel darah merah boleh 
terjadi tanpa melibatkan ketidak normalan pada aras vitamin B12 dan folat di kalangan 
wanita menopaus yang berkaitan dengan kehadiran hiperhomosisteinemia.  
 
Objektif: utama kajian ini adalah untuk mengkaji hubungkait parameter-parameter sel 
darah merah, B12, folat, homosisteina dan polimorfisme gen MTHFR di kalangan 
wanita Melayu yang mengambil rawatan terapi penggantian hormon selepas menopaus 
dan yang tidak mengambil rawatan tersebut. Tujuan lain adalah untuk membandingkan 
paras homosisteina di antara wanita-wanita Melayu sebelum dan selepas menopaus. 
 
 XIX 
Metodologi: Satu kajian keratan silang telah dijalankan di Hospital Universiti Sains 
Malaysia (HUSM). Seratus wanita Melayu menopaus secara semulajadi telah menjadi 
subjek kajian ini. Separuh dari mereka mengambil rawatan terapi penggantian hormon 
dan separuh lagi tidak mengambil rawatan tersebut. Sampel darah diambil dari subjek-
subjek ini untuk ujian-ujian aras vitamin B12, serum dan sel darah merah folat dengan 
menggunakan kaedah ACCESS immunoasai. Aras homosisteina diukur dengan cara 
latex immunoasai secara ‘automated’ sementara pengesanan polimorfisma gen MTHFR 
dilakukan ke atas subjek-subjek terpilih dengan menggunakan reagen attomol MTHFR 
677C>T. Produk dari ujian ‘polymerase chain reaction’ (PCR) kemudiannya di kesan 
dengan menjalankan ujian gel elektroforesis untuk menentukan jenis polimorfisma gen 
ini. Pengiraan darah lengkap dilakukan ke atas semua sampel dengan menggunakan 
mesin analisa hematologi dari Sysmex. 
 
Keputusan: Umur subjek-subjek dalam kajian ini adalah di antara 50 – 60 tahun. 
Terdapat perbezaan yang ketara di antara aras homosisteina di kalangan wanita-wanita 
ini sebelum dan selepas menopaus. Walaubagaimanapun tiada perbezaan yang ketara 
secara statistik bagi paras homosisteina di kalangan wanita yang mengambil dan tidak 
mengambil rawatan terapi penggantian hormon. Purata aras B12 menunjukkan 
perbezaan yang ketara di kalangan wanita yang mengambil dan tidak mengambil 
hormon tersebut. Terdapat hubungkait di antara paras sel darah merah folat dan serum 
folat serta aras homosisteina. Tiada hubungkait di antara homosisteina dan parameter-
parameter sel darah merah, B12 dan serum folat serta polimorfisme gen MTHFR di 
kalangan wanita-wanita ini.   
 XX 
 
Perbincangan/Kesimpulan: Purata aras homosisteina di kalangan wanita Melayu 
menopaus adalah lebih tinggi berbanding dengan sebelum menopaus. Kajian ini 
menunjukkan tiada kesan positif pada aras homosisteina di kalangan wanita yang 
mengambil rawatan terapi penggantian hormon. Hiperhomosisteinemia di kalangan 
wanita Melayu adalah disebabkan oleh pelbagai faktor dan polimorfisma gen MTHFR 
tidak menunjukkan hubungkait yang jelas dalam menyumbangkan keadaan ini dalam 
kajian ini. Kajian serupa yang melibatkan sampel yang lebih besar di masa hadapan 
dapat mengesahkan faktor-faktor penyumbang kepada hiperhomosisteinemia di 
kalangan wanita Melayu termasuk gen-gen lain yang ada kaitan dengan metabolisma 
folat dan B12.  
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RBC PARAMETERS, VITAMIN B12, FOLATE, HOMOCYSTEINE LEVELS 
AND MTHFR GENE POLYMORPHISM IN POSTMENOPAUSAL MALAY 
WOMEN AND THEIR RELATION TO HORMONE REPLACEMENT 
THERAPY 
 
ABSTRACT 
Background: Hyperhomocysteinemia occurs as a result of decreased levels of cofactors 
(vitamin B6, vitamin B12 and folate) and/or reduced efficiency of 
Methylenetetrahydrofolate reductase (MTHFR) enzyme. Hyperhomocysteinemia is an 
independent risk factor for atherosclerosis and may be one of the factors predisposing 
for coronary heart disease (CHD) in postmenopausal women. It is not well known 
whether changes in red blood cells parameters can occur independently of B12 and 
folate abnormalities in postmenopausal women in association with 
hyperhomocysteinemia. 
 
Objectives: The main aim of this study was to investigate the association between red 
cell parameters, B12, folate, homocysteine level and MTHFR gene polymorphisms in 
postmenopausal Malay women on hormone replacement therapy (HRT) and those not 
receiving HRT. Another objective was to compare the homocysteine (Hcy) levels in 
post and premenopausal women. 
 
Methodology: A comparative cross-sectional study was conducted at Hospital 
Universiti Sains Malaysia (HUSM). One hundred women were the subjects of this 
study, half of whom were HRT group and the other half without HRT. Blood samples 
were taken from all the subjects and tested for B12 and folate levels (serum and red 
 XXII 
cell) using ACCESS immunoassay system. The concentration homocysteine was 
measured using an automated latex-enhanced immunoassay method. The MTHFR gene 
detection was performed for selected cases with high and normal Hcy levels using 
attomol® MTHFR 677C>T reagents. PCR products were detected by gel 
electrophoresis in 3.0% agarose gel. Full blood counts (FBC) were done for all samples 
using Sysmex haematology analyzer. 
 
Results: The ages of the subjects were 50-60 years and all of them had natural 
menopause. There was a significant difference in the Hcy levels between 
premenopausal and postmenopausal women. However, Hcy level did not show any 
significant difference in postmenopausal women with and without HRT. B12 was 
significantly lower in subjects in the HRT group compared to non HRT group. There 
was a significant correlation found between serum folate and RBC folate and a 
significant correlation between the levels of Hcy and RBC folate. For the RBC 
parameters, B12 and folate levels and MTHFR gene polymorphisms, no relationship 
was established with Hcy level.  
 
Conclusions: The Hcy level was higher in Malay postmenopausal women (both HRT 
group and non HRT group) compared with premenopausal Malay subjects. HRT did not 
show to have positive effects in on Hcy levels. Hyperhomocysteinaemia in 
postmenopausal Malay women may be multifactorial and the MTHFR gene 
polymorphisms were not found to be associated with this condition. In addition, red cell 
parameters were not shown to have any association with the other variables studied. It 
 XXIII 
was further concluded that bigger sample size with other genetic factors known to be 
involved in B12 and folate metabolism should be included in a similar study to confirm 
the factors contributing to the hyperhomocysteinaemia in postmenopausal women. 
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INTRODUCTION AND LITERATURE REVIEW  
 
 
 
 
 
 
 
 
 
 
  2 
INTRODUCTION AND LITERATURE REVIEW  
 
1.0 Introduction and literature review 
 
Menopause is a natural progression of women’s physiology. However it can be a 
distressing stage for many women and is associated with increased risk of 
cardiovascular disease and osteoporosis. Hormone replacement therapy (HRT) has been 
the basis of the treatment of menopausal state. Despite the proven benefit of HRT, only 
15% of post menopausal women currently use HRT (Amato et al., 2002) and of those 
who started HRT, nearly 30% of them subsequently stopped (Ryan et al., 1992). The 
main reasons for not taking HRT were concerns over its side effects, safety and efficacy 
of the treatment. 
 
 
The Women’s Health Initiative (WHI) Study stated an increase risk in cardiovascular 
disease, breast cancer, stroke and thromboembolic disease with conjugated equine 
estrogen plus medroxyprogesterone acetate compared with placebo (Prestwood et al., 
2003). In view of this problem many women are increasingly turning to alternative 
medicine in an effort to manage their menopausal symptoms (Amato et al., 2002). 
However, there are still questions regarding the effectiveness of HRT and alternative 
medicines in managing menopausal symptoms and complications.  
 
 
 
  3 
1.1 Menopause: 
 
Menopause is defined as cessation of menses for at least 12 months. The diagnosis is 
therefore done retrospectively. Although there is a set point for menopause, it involves 
progressive changes in the hormonal and physiological status in women. Efforts have 
been made to categorize the stages of change in the menopausal continuum.  This 
includes the menopause transitional period or premenopause which is divided into early 
and late phase. The early phase is categorized by irregularity in menstrual cycle of 7 
days different from the normal cycle. In the late transitional period, there are 2 or more 
skipped cycles with an interval of amenorrhea of equal to or more than 60 days. The 
next stage is the actual postmenopausal stage which is divided into two phases, early 
and late menopause. The early menopause lasts for 5 years after the actual cessation of 
the menstrual flow and the late menopause begin after 5 years onwards (Soules et al., 
2001). 
 
 
 The age of menopause has not changed much over the centuries; it has been fairly 
consistent between 50 to 52 years of age. There is also not much difference in the age of 
menopause between regions and across different ethnic groups. There are a variety of 
factors which have been linked to earlier age of menopause such as genetic, null parity, 
smoking, low body mass index, a diet high in vegetables fibers and cereals and 
autoimmune diseases (Lund, 2008). 
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1.2 Physiological changes: 
 
In terms of physiological changes, menopause is generally marked by the decline in the 
oocytes and ovarian function. At birth the numbers of oocytes reach over a million, at 
around forty years of age this is reduced to a few thousands and by the time women 
reach menopause there are few or no oocytes left. It is the depletion of the oocytes that 
eventually leads to the final menstrual period (FMP) and the decline in the ovarian 
hormone production appears to reflect the decline in the ovarian follicle numbers. 
 
The major gonadotrophins involved are the follicle stimulating hormone (FSH) and less 
importantly, the luteinizing hormone (LH). The menopause transition is characterized 
by a dynamic period whereby there is markedly changing hypothalamic-pituitary 
feedback between these hormones produced by the aging ovary. This physiological 
change occurs 10 years prior to the FMP. The hormonal changes in the premenopause 
transition lead to cycle irregularity and dramatic swings in estradiol from undetectable, 
to levels that are several times higher than those observed in those still in early 
reproductive age (Hall, 2004). With the decreasing number of follicles at menopause, 
estradiol level drops until it is no longer adequate to stimulate the endometrium leading 
to amenorrhea. 
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The level of inhibin A and inhibin B are also decreased. These hormones along with 
estradiol are secreted by the developing follicles and their main action is exerting a 
negative feedback to the hypothalamus, therefore reducing the secretion of FSH by the 
pituitary (Burger, 1996). At menopause with the reduced negative feedback by the 
inhibins, FSH tends to be higher to exceed 30 IU/l, a level considered as 
postmenopausal range. 
 
Other hormones are also affected. Androgens secreted by both the adrenals and ovaries 
also decline as women age. However plasma testosterone levels fall only slightly after 
menopause. There is also a difference in the type of estrogen that predominates in the 
postmenopausal state. The main postmenopausal estrogen is estrone, which is produced 
by the conversion of adrenal androstenedione at the peripheral adipose tissue. 
 
 
1.3 Effects of menopause: 
1.3.1 Short term effects:  
 
Vasomotor symptoms: 
 
The most common symptoms experienced by menopausal women are vasomotor 
symptoms. Symptoms include hot flushes and night sweats and it can occur in as many 
as 88% of postmenopausal women (Feldman et al., 1985). However the prevalence of 
the symptoms is different across culture and regions. Women in Germany for example 
experience more hot flushes than those in Papua New Guinea (Kowalcek et al., 2005). 
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A study in Asia showed that only 30% of postmenopausal women in Malaysia 
complained of hot flushes compared to 70% in Thailand (Ko-En et al., 2010).  
 
The mechanism of hot flushes has yet to be clearly defined. Although, many believe 
that the mechanism of hot flushes are related to the fall in estrogen levels, this alone 
does not account for the vasomotor symptoms since the levels of estrogen have not been 
found to correlate with hot flushes. It is hypothesized that the thermoregulatory zone is 
narrowed and more sensitive to subtle changes in core body temperature (Gracia and 
Freeman, 2004).This is thought to be more centrally mediated in the hypothalamus. It is 
still poorly understood how the changes in gonadal hormones level affect the 
thermoregulatory set point. Serotonin and norepinephrines are the other two hormones 
that are pivotal in the mechanism of hot flushes (Rapkin, 2007). Estrogen withdrawal 
may be correlated with a decline in both of these neuropeptides. 
 
Sexual dysfunction: 
 
Sexual dysfunction is highly prevalent during the menopausal transition.  The 
Melbourne Women’s Midlife Health Project which was a prospective study done in 
Australia reported the prevalence of sexual dysfunction to be as high as 88% in this 
group of women (Dennerstein et al., 2002). The reduction in sexual functioning 
adversely affects women’s quality of life and also their sense of femininity (Ko-En et 
al., 2010). 
 
  7 
Estrogen deficiency and androgen deficiency are associated with vaginal atrophy and 
dryness, and decrease in libido respectively (Van Voorhis, 2005), and these will affect 
sexual functioning. The presence of vasomotor symptoms such as night sweats, 
disturbed sleep and depression also lead to diminished libido in postmenopausal women 
which lead to sexual dysfunction (Reed et al., 2007). Hormonal factors are not the only 
factors contributing to sexual dysfunction. Other factors such as loss of sexual partner 
and the aging process itself are also implicated (Nappi and Lachowsky, 2009). 
 
 
Urogenital atrophy: 
 
The role of estrogen in maintaining normal urogenital structure and function is by 
stimulating the growth and development of vaginal epithelium, allowing it to remain 
thick, moist and supple. Vaginal atrophy occurs progressively with the dramatic fall in 
estrogen that occurs just before the final menstrual period.  Clinically it is identified by 
the appearance of thin, pale and dry vaginal epithelium. It also lacks normal rogation 
and the introital size is often reduced. 
 
There is also change in the vaginal pH with decrease in estrogen level. In women of 
reproductive age, vaginal pH is < 4.5. Vaginal pH taken from postmenopausal women 
was found to increase to between 6.0 and 7.5. This may lead to impairment in the local 
defense system and lead to vaginal and urinary tract infection (Van Voorhis, 2005). 
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Symptoms of vaginal atrophy include dryness, itching, vaginitis, and dyspareunia. It is a 
common symptoms reported by postmenopausal women. Vaginal dryness was a 
complaint in 51% of postmenopausal women in Hong Kong (Ko-En et al., 2010). 
 
1.3.2 Long term effects: 
 
The long term complication of menopause which have the greatest impact on health 
status both at the individual and public health levels are cardiovascular disease and 
osteoporosis. 
 
Cardiovascular disease: 
 
Cardiovascular disease is the major cause of death in women worldwide; the third 
Malaysian National Health Survey showed that the main cause of death of Malaysian 
women is due to cardiovascular disease (CVD) (Azmi et al., 2009). The figure is almost 
the same in other parts of developed countries like United State of America. There is a 
difference between the incidence of cardiovascular disease in men and women. The 
incidence of death due to cardiovascular disease is almost unheard of before women 
reach their 50s. However, by the age 70 years the incidence of CVD is equal in men and 
women, suggesting that menopause with it ensuing estrogen deficiency causes a rapid 
acceleration in CVD risk (Azmi et al., 2009). 
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The high incidence in cardiovascular disease is due to the increase in the risk factors 
associated with menopausal state. Menopausal state is associated with the emergence of 
features of metabolic syndrome which includes increase in central or intra abdominal 
body fat, a change toward more atherogenic lipid profile, with increased low density 
lipoprotein particles and increased insulin resistance (Knopp, 2002, Eaten and Anthony 
2002). The mechanism for these changes may be a direct result of ovarian failure or, 
alternatively, an indirect result of the metabolic consequences of central fat 
redistribution with estrogen deficiency in postmenopausal women (Carr, 2003). There is 
however controversy regarding the relationship between weights gains and menopause. 
Previous data suggest that this is more related to aging rather than failure in ovarian 
function (Kolasa, 2002). 
 
Another important risk factor for cardiovascular disease is sedentary life style.  
Menopausal women have been shown to lead more sedentary lifestyle compared to 
younger women (Kolasa, 2002). The role of other risk factors like C-reactive protein 
and homocysteinuria in linking menopause with cardiovascular disease are less well 
established (Kolasa, 2002). More studies need to be done to establish the associations 
between these factors. 
 
When vitamin B12 level decreases too low, the methionine cycle breaks down which 
results in elevated levels of homocysteine. That cycle converts methionine into smaller 
molecules known as S-adenosylmethionine (SAMe). SAMe then breaks down into 
thousands of compounds and proteins that are vital for healthy cells, tissue and organs. 
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One of those breakdown products is homocysteine. Recycling of the homocysteine to 
getting quickly back into methionine needs the assistance of vitamin B12 and folic acid. 
If someone is deficient the normal function of the primary pathway of methionine cycle 
is disrupted and this will result in excess of homocysteine (Nygard et al., 1997). 
 
Excess amount of homocysteine causes blood vessels to lose their elasticity, making it 
harder for them to dilate and damaging the inner lining. These changes allow 
cholesterol, collagen and calcium to attach to the inner walls of the blood vessels where 
they can form sticky deposits called as atherosclerotic plaque. These plaques narrow the 
arteries and increase the risk of artery disease, myocardial infarction, strokes and 
thrombosis clot (Nygard et al., 1997). 
 
Coronary artery disease (CAD) or atherosclerotic heart disease is the end result of the 
accumulation of atheromatous plaques within the walls of the coronary arteries that 
supply the myocardium (the muscle of the heart) with oxygen and nutrients. It is 
sometimes also called coronary heart disease (CHD), but it is not the only cause, 
although CAD is the most common cause of CHD (Tortora & Grabowski 2003). 
 
Osteoporosis: 
 
Osteoporosis is a major health issue since it can lead to fracture with catastrophic 
consequences. The prevalence of osteoporosis is also rising worldwide. In Western 
countries for example United States of America, it is estimated that 54% 
  11 
postmenopausal white women are osteopenic and 30% are osteoporotic as quoted by the 
International Osteoporosis Foundation in 2002. The National Osteoporosis Foundation 
in the USA reported that by the year 2010, about 12 million people over the age of 50 
are expected to have osteoporosis (National Osteoporosis Foundation, 2002). There is 
an erroneous belief that Asian women suffer less osteoporosis and fall compared to their 
western counterpart.  An audit released by the International Osteoporosis Foundation on 
the epidemiology of osteoporosis in Asia revealed that the incidence of hip fractures has 
risen by 2- to 3- fold over the past 30 years (International Osteoporosis Foundation, 
2002).  
 
The WHO defines osteoporosis based on bone mineral density, as a value of less than 
2.5 standard deviation below the average in young women (T-score ≤ -2.5). This 
definition initially was more for epidemiological purpose, however in recent times this 
threshold value has been established as clinical diagnostic tool. 
 
The postmenopausal state is associated with a decrease in the bone mineral density 
which leads to osteoporosis.  There is a widely held belief that the decrease in the 
estradiol level directly contribute to this. Estradiol directly acts on osteoclast by 
reducing the rate of bone resorption (Steinweg, 2002). Bone loss in the postmenopausal 
women, therefore is the result of increase in the rate of bone remodeling and the 
imbalance in osteoclast. 
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The rate of bone loss differs in relation to period of menopause, with the most rapid loss 
occurring early in the premenopausal age. The rate of bone resorption then decrease in 
the late menopause (Sirola et al., 2003). There is also difference regarding the rate of 
bone loss at different site of the body. The lumbar spine has been shown to have more 
osteoporotic changes in early postmenopause compared with other sites such as the 
femur. 
 
 
Menopausal and cancer risk: 
 
Menopause in itself does not cause cancer, but the risk of developing cancer increases 
as a woman ages (Barrett-Connor et al., 2009). Women who have been through 
menopause are more likely to develop cancer because they are older. Among the 
cancers which are associated with late menopause are breast, ovarian, and endometrial 
cancers (Barrett-Connor et al., 2009). (Rossouw et al., 2002). 
 
In terms of breast cancer, menopausal women was found in a study to have an 
additional increase in breast cancer risk  if they had high breast density as measured by 
mammogram (Kerlikowske et al., 2009). This study also showed that advanced-stage 
breast cancer risk was increased 1.7-fold for postmenopausal HRT users who had very 
high density (BIRADS-4) compared to those with average density (BIRADS-2).  The 
association between HRT use in postmenopausal women and the increased risk in breast 
cancer had been shown in various large studies most notably the Women’s Health 
Initiative (WHI) trial (Rossouw et al., 2002). 
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Endometrial cancer is the commonest gynaecological cancer in the developed countries 
and it occurs mainly in the postmenopausal women. The main symptom of endometrial 
cancer is post menopausal bleeding. Postmenopausal women who presented with this 
symptom have to have their endometrial sampled to exclude the presence of any 
abnormality. In term of the effect of combined hormone replacement therapy on the 
cancer incidence, the WHI trial demonstrated the incidence of endometrial cancer 
during the 5-6 years of follow-up was 56 per 100000 person-years than observed in 
women taking the therapy or 13 fewer cases per 100000 person-years than observed in 
women taking placebo (Anderson et al., 2004). This indicated the protective effect of 
progestin against an increased risk of endometrial cancer associated with unopposed 
estrogen. 
 
Ovarian cancer is also not associated with menopause but the incidence of the cancer 
increases as women go into postmenopause. The risk of postmenopausal women having 
the cancer is increased if they have additional risk factors such as low parity, infertility, 
early age of menarche, and late age of menopause (Berek and Hacker, 2005).The theory 
behind the increase risk of ovarian cancer with late age of menopause is thought to be 
related to the incessant ovulation theory. According to this theory with repeated damage 
and trauma to the ovarian epithelium during each ovulatory cycle, there is an increased 
potential for genetic mutation and ovarian neoplasm during the repair process. 
Incidence of ovarian cancer has also been shown to be associated with long term 
combined hormone therapy use (Anderson et al., 2004). 
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Cognitive function: 
 
The effect of estrogen on cognitive function is an intriguing area of research.  It is well 
known that normal aging causes a decline in certain cognitive function, and a decline in 
the estrogen associated with menopause may contribute to this process. In the past 
estrogen therapy has been associated with better performance on memory testing in 
postmenopausal women compared with postmenopausal controls who were not 
receiving estrogen therapy (Kawas et al., 1997). However data from the WHI do not 
show improvement in cognitive function in women taking either combined hormone 
replacement therapy or estrogen only therapy (Rossouw et al., 2002). 
 
1.4 Therapeutic options: 
 
There are three main therapies available in the management of menopausal 
complications which are hormonal replacement therapy (HRT), bisphosphonate and 
selective estrogen receptor modulator. The use of these agents is increasingly being 
challenged by the alternative medicines especially after the release of the result of 
Women Health Initiative Study. Among the popular alternative medicine used in 
menopausal symptoms are soy products, black cohosh, dong quai, red clover, ginseng 
and evening primrose oil (Black et al., 2006). 
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Hormone replacement therapy: 
 
Hormone replacement therapy (HRT) has long been the mainstay of the treatment of 
menopausal symptoms and its complications especially osteoporosis. The essential 
component in HRT is estrogen, which is combined with progestogen to prevent 
endometrial hyperplasia in women with intact uterus (Barrett-Connor et al., 2006). 
 
The oral estrogen commonly used is estradiol valerate 1mg or 2 mg, conjugated equine 
estrogen (CEE) 0.625 mg or 1.25 mg and estrone 1.25 mg.  The minimum effective 
dose of estrogen has long been questioned. After the WHI, more interest has been 
shown to the use of low dose estrogen. The usually prescribed dosage of 
postmenopausal estrogen therapy has declined progressively and in the past 10 years, 
use of lower dose HRT has grown in popularity. Low-estrogen formulations that are 
starting to be used recently are 0.3mg CEE, 0.45 mg CEE and 0.5 mg or 1mg micronzed 
oral 17-estradiol and these are considered low dose HRT. This lower dose of oestrogen 
is also beneficial in terms of reduced breast tenderness, an effect that should also help to 
improve compliance and acceptability, particularly in older women (Barrett-Connor et 
al., 2006). 
 
The progestogens used in HRT are nearly all synthetic. They are added to reduce the 
risk of endometrial hyperplasia and malignancy. The two classes of progestogens 
commonly used for in combination with estradiol is C-21 group (medroxyprogesterone 
acetate, dydrogesterone) derived from native progestogens and a C-19-nor group 
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(norethisterone, norgestrel) derived from testosterone. Dydrogesterone, a retro-
progesterone derivative in particular is structurally closest to the body’s own 
progesterone and fairly neutral effect on the protective properties of estrogen on bone 
metabolism (Schindler et al., 2003). 
 
Currently progestogens are mainly given orally, however transdermal formulations of 
levonogestrel and norethisterone are becoming available. Progestogen is only required 
in women with intact uterus. It can be given either for 10-14 days every four weeks or 
for 14 days every 13 weeks or even continuously every day. The continuous 
formulations is suitable for women with early or late postmenopause while the monthly 
sequential regime is given for those in menopausal transition or premenopause stage 
(Cieraad et al., 2006). 
 
The controversy with HRT started to appear after the release of the results from 
Women’s Health Initiative (WHI) trial in 2002. The trial involved 27,347 
predominantly healthy postmenopausal women aged 50 to 79 years old from 40 centers 
across America. The women were randomized to either receive 0.625 mg/d of CEE or 
0.625mg/d CEE plus 2.5 mg/d of medroxyprogesterone acetate (MPA) based on their 
hysterectomy status and they were compared with placebo (Rossouw et al., 2002). The 
aim of the trial was to see the effect of HRT to a ‘global health index’ which includes 
coronary heart disease, breast cancer, fractures, stroke, pulmonary embolism, colorectal 
cancer and endometrial cancer (Rossouw et al., 2002). 
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For every 10,000 women per year who were taking combination HRT, there were eight 
more invasive breast cancers, seven more coronary heart disease events, eight more 
strokes and eight more pulmonary embolisms than in the placebo group. Physicians and 
patients were encouraged to use HRT for the shortest duration possible since the biggest 
increase in breast cancer was seen after 5 years. Similar result in term of breast cancer 
risk was seen in the Million Women Study conducted in England (Beral, 2003).The 
main limitation of WHI trial is that they include older women who were 
postmenopausal for many years and the result therefore cannot be extrapolated to the 
younger postmenopausal women.  
 
A variety of drugs are used for prevention and treatment of CHD. Hormone replacement 
therapy (oestrogen) was reported to give benefit effects to reduce the risk of CHD in 
postmenopausal women (Smolders et al., 2005). 
 
The main indication for HRT use currently is for the treatment of postmenopausal 
symptoms and it is no longer recommended for disease prevention (Dull, 2006). A 
Cochrane review concluded that oral estrogen or combined estrogen and progestogen 
hormone replacement therapy greatly reduces the frequency and severity of hot flushes 
and night sweats (MacLennan et al., 2004). The maximum benefit is usually seen within 
three months of treatment. 
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HRT has long been proven beneficial in the treatment of postmenopausal osteoporosis. 
Both observational studies and randomized clinical trial have demonstrated that 
estrogens or estrogens plus progestin increase bone density and reduce the risk of 
fractures by preventing bone loss mainly in the vertebral bone (Huot et al., 2008). 
 
Recently, there has been increasing evidence that it is also beneficial in preventing 
fracture in the non-vertebral bone. A 5 year randomized controlled trial was done to 
compare the incidence of new non-vertebral bone fractures in non-osteoporotic 
postmenopausal women taking HRT or low dose vitamin D. This study showed the 
incidence of non-vertebral bone fractures is significantly reduced compared to the 
vitamin D group. The fall in fracture rate is also consistent with the increase in bone 
mass (Komulainen et al., 2008). 
 
Femoston Conti is one of the examples of low dose hormone replacement therapy. It 
contains 17β-estradiol plus dydrogesterone with a multiple dosing range combination. 
The doses of estradiol include 1 and 2 mg, while the doses of dydrogesterone include 5, 
10 and 20 mg. There are multiple studies which have shown the effectiveness of this 
treatment in managing menopausal symptoms and having bone protective effects. A 
study comparing the 17β-estradiol / dydrogesterone with conjugated equine 
estrogens(CEE)/norgestrel have shown that it was equally effective in managing 
climacteric symptoms while showing some advantages in terms of lipid profile and 
incidence of bleeding (Cieraad et al., 2006). A combination of 1 mg 17β-estradiol with 
a combination of 5, 10 and 20 mg of dydrogesterone had also been shown to have 
